RMP
VRTX icon

Richards, Merrill & Peterson’s Vertex Pharmaceuticals VRTX Stock Holding History

Richards, Merrill & Peterson’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18
Closed -$8.73K – 467
2025
Q1 		$8.73K Hold
18
– – ﹤0.01% 407
2024
Q4 		$7.25K Buy
+18
New +$8.34K ﹤0.01% 407

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Richards, Merrill & Peterson's VRTX Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 18 shares — an estimated $8.73K sold.

Richards, Merrill & Peterson first reported a position in VRTX in Q4 2024 and held it in 2 quarters. The position peaked at $8.73K in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 18 Vertex Pharmaceuticals shares in Q2 2025, an estimated $8.73K.
  • Richards, Merrill & Peterson first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's Vertex Pharmaceuticals position peaked at $8.73K in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.